10x Genomics Inc. recently held a conference call to discuss its financial results for the first quarter ended June 30, 2025. The call was attended by CEO and Co-Founder Serge Saxonov, Chief Financial Officer Adam Taich, and Senior Director, Head of Investor Relations and Strategic Finance, Cassie Corneau. During the call, management highlighted the company's advancements and strategic initiatives. Notably, they discussed the use of their Chromium Universal 5' assay by Xaira Therapeutics to produce the largest publicly-available, genome-wide Perturb-seq dataset to date. Furthermore, 10x Genomics announced the extension of its partnership with the Arc Institute to support the Virtual Cell Challenge, which aims to develop computational models of biology. Management emphasized the importance of understanding cells to advance health and disease research, stating, "If we can model cells and perturbations computationally using AI, we can guide the discovery of new drugs." Additionally, they announced the acquisition of Scale Biosciences to accelerate innovation across their Chromium platform. The full transcript can be accessed through the link below.